Opko Health Inc (OPK) 10.31 $OPK OPKO Health to Present

New Post Public Reply Private Reply Replies (0) Message Board

Sep 20, 2016 at 1:05 AM

Opko Health Inc (OPK) 10.31 $OPK

OPKO Health to Present at the Ladenburg Thalmann 2016 Healthcare Conference
BusinessWire - Mon Sep 19, 7:30AM CDT
OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27th, 2016 at 10:30 AM (ET).
OPK: 10.31 (+0.10)

Verizon Communications, Twilio Inc., Opko Health, Starbucks, and EMC Corporation and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Thu Sep 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EMC, OPK, SBUX, TWLO, and VZ.
SBUX: 53.01 (-0.73), OPK: 10.31 (+0.10), TWLO: 57.28 (+0.53), EMC: 29.05 (+0.28), VZ: 51.20 (-0.68)

OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories
BusinessWire - Tue Sep 13, 7:30AM CDT
OPKO Health, Inc. (Nasdaq: OPK) announces the appointment of Jane Pine Wood, Esq. as Chief Legal and Compliance Officer of its wholly owned subsidiary, BioReference Laboratories, effective October 1, 2016.
OPK: 10.31 (+0.10)

OPKO to Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data at the 55th Annual Meeting of the European Society for Paediatric Endocrinology
BusinessWire - Tue Sep 06, 7:30AM CDT
OPKO Health, Inc. (NASDAQ:OPK) will present abstracts at the 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) to be held in Paris, France on September 10-12, 2016.
OPK: 10.31 (+0.10)

Cocrystal Pharma Receives Investment Through Private Placement
Marketwired - Fri Sep 02, 7:30AM CDT
BOTHELL, WA and ATLANTA, GA--(Marketwired - September 02, 2016) - On September 1, 2016, Cocrystal Pharma, Inc. (OTCQB: COCP) (the "Company"

closed on proceeds of $4,008,201 in a private placement offering (the "Offering"

of 9,776,100 shares of the Company's common stock at a purchase price of $0.41 per share. The purchasers included three members of the Company's board of directors, including Chairman Dr. Raymond F. Schinazi, Interim Chief Executive Officer Dr. Gary Wilcox, and Dr. David Block. In addition, OPKO Health, Inc., of which the Company's director Dr. Phillip Frost is Chairman and Chief Executive Officer, invested in the Offering.
OPK: 10.31 (+0.10)

OPKO Health to Participate in Upcoming September Conferences
BusinessWire - Thu Sep 01, 3:43PM CDT
OPKO Health, Inc. (Nasdaq: OPK), today announced that senior management will participate in the 11th Annual Wells Fargo Securities Healthcare Conference taking place September 7-8, 2016 in Boston and the 9th Annual Barrington Research Fall Investment Conference taking place on September 8, 2016 in Chicago.
OPK: 10.31 (+0.10), WFC: 46.01 (+0.58)

SmarTrend Watching for Potential Pullback in Shares of Opko Health After 1.32% Gain
Comtex SmarTrend(R) - Thu Sep 01, 2:59PM CDT
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $9.20 to a high of $9.54. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $9.46 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OPK: 10.31 (+0.10)

InvestorsObserver releases covered-call reports for Freeport-McMoRan, Potash Corporation of Saskatchewan, Smith & Wesson, JetBlue and Opko Health
PR Newswire - Wed Aug 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCX, JBLU, OPK, POT, and SWHC.
OPK: 10.31 (+0.10), FCX: 10.01 (+0.07), POT: 15.96 (-0.03), JBLU: 17.22 (+0.07), SWHC: 27.97 (+0.64)

OPKO Health Completes Acquisition of Transition Therapeutics
BusinessWire - Wed Aug 31, 12:00AM CDT
OPKO Health, Inc. (NASDAQ: OPK), announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. (NASDAQ: TTHI, TSX: TTH), by way of a plan of arrangement (the "Arrangement"

which was approved by Transition Therapeutics' shareholders at their meeting held on August 25, 2016. Pursuant to the Arrangement, shareholders of Transition Therapeutics will receive an aggregate of approximately 6.4 million shares of OPKO common stock, or 0.1657 shares of OPKO common stock for each common share of Transition Therapeutics. The Arrangement was approved by the Ontario Superior Court of Justice in its final order dated August 29, 2016.
TTH.TO: 1.93 (+0.01), OPK: 10.31 (+0.10), TTHI: 1.52 (unch)

Transition Therapeutics Shareholders Approve Acquisition by OPKO Health
BusinessWire - Fri Aug 26, 7:52AM CDT
OPKO Health, Inc. (Nasdaq: OPK), announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. (NASDAQ:TTHI, TSX: TTH) holding approximately 93% of the outstanding common shares, voted to approve the previously announced agreement under which OPKO Health will acquire Transition Therapeutics. The acquisition is subject to final approval of the Ontario Superior Court Justice (the "Court"

. The Court hearing for the final order is scheduled to take place on August 29, 2016, and the acquisition is expected to close on September 1, 2016.
TTH.TO: 1.93 (+0.01), OPK: 10.31 (+0.10), TTHI: 1.52 (unch)

Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health
PR Newswire - Wed Aug 24, 6:35AM CDT
Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:
OPK: 10.31 (+0.10), SRPT: 48.94 (+20.79), MNKD: 0.70 (unch), CELG: 107.73 (-0.81), CELGZ: 1.20 (-0.01)

Look for Shares of Opko Health to Potentially Rebound after Yesterday's 2.96% Sell Off
Comtex SmarTrend(R) - Tue Aug 23, 3:19PM CDT
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $9.37 to a high of $9.91. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $9.70 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
OPK: 10.31 (+0.10)

OPKO Health Responds to Law Firm Notice of Investigation
BusinessWire - Tue Aug 23, 11:46AM CDT
OPKO Health, Inc. (NYSE:OPK), is aware of a press release by Purcell Julie & Lefkowitz, LLP, a class action litigation firm, that it is investigating the Company for an alleged potential breach of fiduciary duty claim involving the Company's Board of Directors. The Company has not received any notification or information from Purcell Julie & Lefkowitz regarding its investigation of any potential breach of fiduciary duty or other claim against OPKO's Board of Directors. Nor have any such claims or allegations been made by any shareholders, other law firms or regulatory bodies. OPKO's attempts to contact the law firm have gone unanswered. The Company does not believe there is any basis or merit behind the investigation and will vigorously defend itself should any formal allegations or claims be made.
OPK: 10.31 (+0.10)

BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP(R) Cell Therapy System for the Treatment of Heart Failure
BusinessWire - Tue Aug 23, 7:34AM CDT
BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, announced today that it has entered into a definitive agreement to merge with Tiger X Medical, Inc. (OTCPink: CDOM). The combined entity, which will change its name to BioCardia following the closing, will trade on the OTC Markets and will focus solely on the business of BioCardia.
OPK: 10.31 (+0.10), BCDA: ()

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating OPKO Health, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Aug 23, 6:10AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of OPKO Health, Inc. (NASDAQ: OPK).
OPK: 10.31 (+0.10)

Arno Completes $2.8 Million Private Placement
BusinessWire - Tue Aug 16, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has completed a private placement of its common stock and common stock purchase warrants that will result resulting in gross proceeds to the Company of approximately $2.8 million. The financing was led by the Company's existing investors, including affiliates of Chairman, Arie Belldegrun, MD, OPKO Health, Inc., Commercial Street Capital LLC, Pontifax, Bonderman Family Limited Partnership, Perceptive Advisors LLC and Auriga Capital Management. The Company intends to use the proceeds from this financing to fund its ongoing clinical development of onapristone, its lead product candidate, and for general corporate purposes.
OPK: 10.31 (+0.10)

Global Mitogen-Activated Protein Kinase 8 Pipeline Report 2016 - Celgene Corporation, Eisai Co., Ltd. & OPKO Health, Inc. - Research and Markets
BusinessWire - Fri Aug 12, 9:59AM CDT
Research and Markets has announced the addition of the "Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Pipeline Review, H1 2016" report to their offering.
OPK: 10.31 (+0.10), CELGZ: 1.20 (-0.01)

Facebook, Opko Health, ZELTIQ Aesthetics, Palo Alto Networks, and Yelp and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Aug 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FB, OPK, PANW, YELP, and ZLTQ.
ZLTQ: 39.39 (-1.08), OPK: 10.31 (+0.10), FB: 128.65 (-0.42), YELP: 37.29 (-0.66), PANW: 150.74 (+1.64)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Employment Law Suit Hits ABC: Alleged Wage Violations

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...